

Awarded for a research or analytical project that has demonstrated a significant impact on the UK business

Highly Commended Entries:

Transforming Expectations in Adjuvant Melanoma



John Grime
Strategic North



Chris Lewis-DeBoos
Strategic North



Amy Walker
Strategic North



Sachin Gholap
BMS UK



Lara Lucchese
BMS UK

Executive Summary:

In 2018, the melanoma community was awaiting a breakthrough. BMS had the opportunity to offer treatment where none had existed, for patients with huge unmet need. Adjuvant treatment has proven to be game-changing, relieving the significant anxiety of 'watchful waiting' for high risk patients, and allowing them the choice to proactively reduce their risk and improve chance of cure. Fast-forward to 2019, and across the UK patients are now able to choose an active treatment option, confidently communicated by their treatment team, rather than anxiously wait and hope...

From stellar idea to supernova



Aida Ortola
Novartis
Pharmaceuticals
UK Ltd.



Katy Irving
HRW



Erik Thompson
Novartis
Pharmaceuticals
UK Ltd.



Sharon Coyle
Novartis
Pharmaceuticals
UK Ltd.

Executive Summary:

When Novartis faced the challenge of seeking 'deeper insights' in a small but challenging research project, they never expected what the results would deliver. The application of behaviour change science in the results from HRW were so actionable that the team were inspired to continue the partnership to apply this model more broadly: taking it beyond thinking about customer barriers, to using promotional tactics more smartly, designing new interventions, and distinguishing between 'real' and 'false' objections. Within a year, the theoretical model and the solutions it enables has 'caught fire' across Novartis; being used in marketing, sales, and training franchise-wide.

Searching for needles in a million haystacks: helping ensure the accurate diagnosis of a rare haematological condition



Jane Takata
Alexion



Charlotte Sugden Heron
Synergy
Healthcare
Research Ltd



Jon Freeman
Synergy
Healthcare
Research Ltd

Executive Summary:

A typical haemolytic uraemic syndrome (aHUS) is an extremely rare condition with only about 140 known patients in England – but it is estimated that the diagnosis is missed in over 50% of patients. Research provided powerful insights in terms of the key barriers to the diagnosis of aHUS and how best to develop educational support that will engage haematologists to improve the diagnosis of a rare condition and thus ensure eligible patients receive life-saving treatment.


Question. Challenge. Refocus.



Claire Derbyshire
Grünenthal



Simon Barnes
THE
PLANNING
SHOP



Dean Smith
THE
PLANNING
SHOP



Rawaa Shami
THE
PLANNING
SHOP



Sonny Matharoo
THE
PLANNING
SHOP

Executive Summary:

Question: The company wanted definitive confirmation around key customer groups to target and the patient flow to drive strategy for 2019 Challenge: At each phase the findings challenged the company's thinking and forced them to re-evaluate what they knew about who their stakeholders were and where the opportunity really lay Refocus: Conclusions lead to a refocus of the brand strategy, expanding customer types & patient pools which had not previously been considered, leading to a new brand direction for 2019 & beyond.

"SurveyHealthcare is a proud sponsor of the 2019 BOBI award for 'Best Business Impact'. At SHC, we are committed to providing an innovative and integrated approach to support healthcare market research agencies in making decisions that impact health outcomes. We are honoured to recognize likeminded researchers who have demonstrated a significant impact across the UK client business."

Sponsored by






best of business intelligence

Best Business Impact

Awarded for a research or analytical project that has demonstrated a significant impact on the UK business

Highly Commended Entries:

The Success of Embedding Analytics to Support the NHS in Optimising the Use of Herceptin SC, Herceptin IV and Trastuzumab Biosimilars in Individual Accounts



Max Bourgognon
Roche Products Limited



Vanessa Regester
Roche Products Limited



James Ambler
Moor Consulting

Executive Summary:

To support our Breast Cancer franchise, we developed comprehensive analytical solutions, which aggregated information collected from our field forces and sales performance. Such output was critical to gaining in-depth market understanding, enabling dissemination of actionable insights throughout the business and allowing tailoring of customer messaging in real time. This allowed Roche to support the NHS in optimising the use of Herceptin SC, Herceptin IV and trastuzumab biosimilar in individual accounts ensuring the most appropriate product is prescribed. This created a positive Roche customer experience, beneficial to both the current portfolio and future brand launches within the Breast Cancer franchise.

Combining qualitative research with granular quantitative research to identify marginal gains within the 3rd line setting in colorectal cancer



Zoë Carter
Servier Laboratories Ltd



Laurence Olding
Bryter



Isabel Wood
Bryter

Executive Summary:

Lonsurf is the UK's market-leading product for third line (3L) treatment of advanced/metastatic colorectal cancer. Bryter completed a mixed methodology comprising in-depth interviews and an online survey including perceptual questioning supplemented by patient record tasks. Findings defined the treatment landscape, mapped patient profiles, and gave a deep-dive into physician behaviors and attitudes, uncovering detailed perceptions of Lonsurf and competitors. Bryter's results provided new understanding of why physicians are limiting Lonsurf use, allowing Servier to focus on a 'marginal gains' sales strategy for reaching attainable increases to market share.

"SurveyHealthcare is a proud sponsor of the 2019 BOBI award for 'Best Business Impact'. At SHC, we are committed to providing an innovative and integrated approach to support healthcare market research agencies in making decisions that impact health outcomes. We are honoured to recognize likeminded researchers who have demonstrated a significant impact across the UK client business."

Sponsored by

